211 related articles for article (PubMed ID: 16418498)
1. Prognostic biomarkers in diffuse large B-cell lymphoma.
Lossos IS; Morgensztern D
J Clin Oncol; 2006 Feb; 24(6):995-1007. PubMed ID: 16418498
[TBL] [Abstract][Full Text] [Related]
2. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma.
Wu G; Keating A
Cancer; 2006 Jan; 106(2):247-57. PubMed ID: 16342164
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.
Shipp MA; Ross KN; Tamayo P; Weng AP; Kutok JL; Aguiar RC; Gaasenbeek M; Angelo M; Reich M; Pinkus GS; Ray TS; Koval MA; Last KW; Norton A; Lister TA; Mesirov J; Neuberg DS; Lander ES; Aster JC; Golub TR
Nat Med; 2002 Jan; 8(1):68-74. PubMed ID: 11786909
[TBL] [Abstract][Full Text] [Related]
5. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
[TBL] [Abstract][Full Text] [Related]
6. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
7. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Obermann EC; Went P; Pehrs AC; Tzankov A; Wild PJ; Pileri S; Hofstaedter F; Dirnhofer S
Oncol Rep; 2005 Dec; 14(6):1461-7. PubMed ID: 16273239
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy for relapsed/refractory diffuse large B cell lymphoma.
Seshadri T; Kuruvilla J; Crump M; Keating A
Biol Blood Marrow Transplant; 2008 Mar; 14(3):259-67. PubMed ID: 18275892
[TBL] [Abstract][Full Text] [Related]
9. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathogenesis of diffuse large B-cell lymphoma.
Lossos IS
J Clin Oncol; 2005 Sep; 23(26):6351-7. PubMed ID: 16155019
[TBL] [Abstract][Full Text] [Related]
11. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
[TBL] [Abstract][Full Text] [Related]
12. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome.
Tzankov A; Gschwendtner A; Augustin F; Fiegl M; Obermann EC; Dirnhofer S; Went P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2125-32. PubMed ID: 16609025
[TBL] [Abstract][Full Text] [Related]
13. Conditional survival of patients with diffuse large B-cell lymphoma.
Moller MB; Pedersen NT; Christensen BE
Cancer; 2006 May; 106(10):2165-70. PubMed ID: 16586498
[TBL] [Abstract][Full Text] [Related]
14. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
15. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
[TBL] [Abstract][Full Text] [Related]
16. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited.
Segal MR
Biostatistics; 2006 Apr; 7(2):268-85. PubMed ID: 16284340
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
[TBL] [Abstract][Full Text] [Related]
18. Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas.
Shim HK; Lee WW; Park SY; Kim H; So Y; Kim SE
Nucl Med Biol; 2009 Feb; 36(2):191-7. PubMed ID: 19217531
[TBL] [Abstract][Full Text] [Related]
19. Molecular diagnosis of lymphoma: outcome prediction by gene expression profiling in diffuse large B-cell lymphoma.
Last K; Debarnardi S; Lister TA
Methods Mol Med; 2005; 115():15-63. PubMed ID: 15998962
[TBL] [Abstract][Full Text] [Related]
20. Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas.
Ramuz O; Bouabdallah R; Devilard E; Borie N; Groulet-Martinec A; Bardou VJ; Brousset P; Bertucci F; Birg F; Birnbaum D; Xerri L
Int J Oncol; 2005 Jan; 26(1):151-7. PubMed ID: 15586235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]